Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation

F Duska, M Fric, P Waldauf, J Pazout, M Andel, P Mokrejs, P Tuma, J Pachl

. 2008 ; 36 (6) : 1707-1713.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc11002936

Grantová podpora
NR8230 MZ0 CEP - Centrální evidence projektů

OBJECTIVES: To estimate the efficacy and metabolic effects of growth hormone substitution as intravenous pulses together with alanyl-glutamine supplementation and tight blood glucose control in prolonged critical illness. DESIGN: Prospective double-blind, randomized trial with open-label control arm. SETTING: Intensive care unit of tertiary level hospital. PATIENTS: Thirty multiple trauma patients (median Injury Severity Score 34). INTERVENTIONS: Patients were randomized, at day 4 after trauma, to receive intravenous alanyl-glutamine supplementation (0.3 g/kg x day(-1) from day 4 until day 17) and intravenous growth hormone (administered days 7-17, full dose 50 microg/kg x day(-1) from day 10 onward) (group 1, n = 10) or alanyl-glutamine and placebo (group 2, n = 10). Group 3 (n = 10) received isocaloric isonitrogenous nutrition (proteins 1.5 g/kg x day(-1)) without alanyl-glutamine. MEASUREMENTS AND MAIN RESULTS: Cumulative nitrogen balance for the whole study period was -97 +/- 38 g of nitrogen for group 1, -193 +/- 50 g of nitrogen for group 2, and -198 +/- 77 g of nitrogen for group 3 (p < .001). This represents a daily saving of 300 g of lean body mass in group 1. Insulin-mediated glucose disposal, during euglycemic clamp, as a measure of insulin sensitivity, significantly worsened between days 4 and 17 in group 1 but improved in groups 2 and 3. Group 1 required significantly more insulin to control blood glucose, resulting in higher insulinemia (approximately 70 mIU in group 1 vs. approximately 25 mIU in groups 2 and 3). Despite this, growth hormone treatment caused an increase in plasma nonesterified fatty acid (approximately 0.5-0.6 mM in group 1 in comparison with approximately 0.2-0.3 mM in groups 2 and 3) but did not influence lipid oxidation. There were no differences in morbidity, mortality, or 6-month outcome among the groups. CONCLUSIONS: Treatment with frequent intravenous pulses of low-dose growth hormone together with alanyl-glutamine supplementation improves nitrogen economy in patients with prolonged critical illness after multiple trauma but worsens insulin sensitivity. Tight blood glucose control is possible but requires higher doses of insulin.

Citace poskytuje Crossref.org

000      
02535naa 2200625 a 4500
001      
bmc11002936
003      
CZ-PrNML
005      
20131002105432.0
008      
110225s2008 xxu e eng||
009      
AR
024    __
$a 10.1097/ccm.0b013e318174d499 $2 doi
035    __
$a (PubMed)18496372
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Duška, František, $d 1976- $7 mzk2007386027
245    10
$a Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation / $c F Duska, M Fric, P Waldauf, J Pazout, M Andel, P Mokrejs, P Tuma, J Pachl
314    __
$a Department of Anesthesia and Critical Care Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic, EU. fduska@yahoo.com
520    9_
$a OBJECTIVES: To estimate the efficacy and metabolic effects of growth hormone substitution as intravenous pulses together with alanyl-glutamine supplementation and tight blood glucose control in prolonged critical illness. DESIGN: Prospective double-blind, randomized trial with open-label control arm. SETTING: Intensive care unit of tertiary level hospital. PATIENTS: Thirty multiple trauma patients (median Injury Severity Score 34). INTERVENTIONS: Patients were randomized, at day 4 after trauma, to receive intravenous alanyl-glutamine supplementation (0.3 g/kg x day(-1) from day 4 until day 17) and intravenous growth hormone (administered days 7-17, full dose 50 microg/kg x day(-1) from day 10 onward) (group 1, n = 10) or alanyl-glutamine and placebo (group 2, n = 10). Group 3 (n = 10) received isocaloric isonitrogenous nutrition (proteins 1.5 g/kg x day(-1)) without alanyl-glutamine. MEASUREMENTS AND MAIN RESULTS: Cumulative nitrogen balance for the whole study period was -97 +/- 38 g of nitrogen for group 1, -193 +/- 50 g of nitrogen for group 2, and -198 +/- 77 g of nitrogen for group 3 (p < .001). This represents a daily saving of 300 g of lean body mass in group 1. Insulin-mediated glucose disposal, during euglycemic clamp, as a measure of insulin sensitivity, significantly worsened between days 4 and 17 in group 1 but improved in groups 2 and 3. Group 1 required significantly more insulin to control blood glucose, resulting in higher insulinemia (approximately 70 mIU in group 1 vs. approximately 25 mIU in groups 2 and 3). Despite this, growth hormone treatment caused an increase in plasma nonesterified fatty acid (approximately 0.5-0.6 mM in group 1 in comparison with approximately 0.2-0.3 mM in groups 2 and 3) but did not influence lipid oxidation. There were no differences in morbidity, mortality, or 6-month outcome among the groups. CONCLUSIONS: Treatment with frequent intravenous pulses of low-dose growth hormone together with alanyl-glutamine supplementation improves nitrogen economy in patients with prolonged critical illness after multiple trauma but worsens insulin sensitivity. Tight blood glucose control is possible but requires higher doses of insulin.
650    _2
$a APACHE $7 D018806
650    _2
$a dospělí $7 D000328
650    _2
$a amoniak $x moč $7 D000641
650    _2
$a krevní glukóza $x metabolismus $7 D001786
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a nepřímá kalorimetrie $7 D002153
650    _2
$a kreatinin $x moč $7 D003404
650    _2
$a péče o pacienty v kritickém stavu $x metody $7 D003422
650    _2
$a dipeptidy $x aplikace a dávkování $7 D004151
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a energetický metabolismus $x účinky léků $7 D004734
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidský růstový hormon $x aplikace a dávkování $7 D019382
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a inzulinová rezistence $x fyziologie $7 D007333
650    _2
$a délka pobytu $7 D007902
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a polytrauma $x farmakoterapie $x mortalita $x patofyziologie $7 D009104
650    _2
$a dusík $x moč $7 D009584
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prospektivní studie $7 D011446
650    _2
$a pulzní dávkování léků $7 D020551
650    _2
$a míra přežití $7 D015996
650    _2
$a financování organizované $7 D005381
655    _2
$a srovnávací studie $7 D003160
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Fric, Michal. $7 xx0241106
700    1_
$a Waldauf, Petr $7 xx0085547
700    1_
$a Pažout, Jaroslav $7 xx0137181
700    1_
$a Anděl, Michal, $d 1946- $7 jn19981228006
700    1_
$a Mokrejš, Pavel. $7 _AN054765
700    1_
$a Tůma, Petr $7 xx0105786
700    1_
$a Pachl, Jan, $d 1949- $7 nlk19990073644
773    0_
$t Critical Care Medicine $w MED00009514 $g Roč. 36, č. 6 (2008), s. 1707-1713
910    __
$a ABA008 $b x $y 1
990    __
$a 20110413123548 $b ABA008
991    __
$a 20131002105949 $b ABA008
999    __
$a ok $b bmc $g 830353 $s 694924
BAS    __
$a 3
BMC    __
$a 2008 $b 36 $c 6 $d 1707-1713 $m Critical care medicine $n Crit Care Med $x MED00009514
GRA    __
$a NR8230 $p MZ0
LZP    __
$a 2011-2B/dkme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé